α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with theIL28Bminor genotype

2013 ◽  
Vol 86 (3) ◽  
pp. 461-472 ◽  
Author(s):  
Noritomo Shimada ◽  
Akihito Tsubota ◽  
Masanori Atsukawa ◽  
Hiroshi Abe ◽  
Makiko Ika ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Treatment Failure ◽  
Chronic Hepatitis C ◽  
Surrogate Marker ◽  
Japanese Patients ◽  
Triple Combination ◽  
Triple Combination Therapy ◽  
Genotype 1B

scholarly journals Efficacy and Safety of Glecaprevir/Pibrentasvir Combination Therapy in Genotype 1b Chronic Hepatitis C Patients with and without Cirrhosis Undergoing Hemodialysis

Kanzo ◽  
2018 ◽  
Vol 59 (10) ◽  
pp. 578-580
Author(s):  
Masanori Atsukawa ◽  
Chisa Kondo ◽  
Makoto Nakamuta ◽  
Hidenori Toyoda ◽  
Takashi Kumada ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Chronic Hepatitis C ◽  
Efficacy And Safety ◽  
Genotype 1B ◽  
Chronic Hepatitis C Patients

Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C

2014 ◽  
Vol 46 (8) ◽  
pp. 738-743 ◽  
Author(s):  
Masanori Atsukawa ◽  
Akihito Tsubota ◽  
Noritomo Shimada ◽  
Hiroshi Abe ◽  
Chisa Kondo ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Treatment Outcomes ◽  
Chronic Hepatitis C ◽  
Genotype 1B

scholarly journals Response factors to pegylated interferon-alfa/ribavirin treatment in chronic hepatitis C patients genotype 1b

2014 ◽  
Vol 66 (1) ◽  
pp. 193-201 ◽  
Author(s):  
Snezana Jovanovic-Cupic ◽  
S. Glisic ◽  
M. Stanojevic ◽  
N. Vasiljevic ◽  
T. Bojic-Milinovic ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Chronic Hepatitis C ◽  
Sustained Viral Response ◽  
Therapy Response ◽  
Pegylated Interferon ◽  
Response To Therapy ◽  
Genotype 1B

Hepatitis C virus infection is the most common chronic blood-borne infection and one of the most important causes of chronic liver disease. Knowing the predictors associated with pegylated interferon/ribavirin (PEG-IFN/RBV) combination therapy response is important for evidence-based treatment recommendations. The goal of this study was to identify host and viral factors of response to PEG-IFN/RBV treatment in chronic hepatitis C genotype 1b patients. We have examined the relationship between gender, age, level of alanine aminotransferase (ALT), viral load and liver fibrosis progression on therapy response. ALT level and viral load were evaluated before starting treatment with combination therapy. The elevated levels of ALT and route of HCV transmission were found to be significantly associated with the response to therapy in HCV-infected patients. Our findings may be useful for estimating a patient?s likelihood of achieving sustained viral response.

Sign in / Sign up

Export Citation Format

Share Document